Project Grant W81XWH2211066

The National Institutes of Health (NIH) Office of Research Infrastructure Programs (ORIP) awarded a $257,429 Project Grant (CFDA 93.351) to the University of Miami to investigate immunomodulatory drug interventions for preventing immune responses toward adeno-associated virus (AAV)-delivered anti-HIV antibodies. The 2-year project aims to induce tolerance toward AAV-delivered antibodies using synergistic drug treatments and explore the potential of nucleoside-modified mRNA delivery to prevent...

This $704,795 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Baylor College of Medicine supports the development of a novel cell-based immunomodulation therapy to suppress lung inflammation and promote repair in Acute Respiratory Distress Syndrome (ARDS). The project aims to engineer retinal pigment epithelial (RPE) cells to produce anti-inflammatory cytokines IL-1RA and IL-10 and encapsulate them in alginate-based...

This $240,878 Project Grant, awarded on June 2, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports planning activities for a future clinical trial to evaluate a novel treatment strategy for Mycobacterium abscessus pulmonary disease. The key objectives are to: 1) develop the detailed trial protocol and documentation, 2) secure the study drug and placebo, 3) identify additional enrollment...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $873,736 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Los Angeles (CHLA) to study risk stratification markers for pediatric acute respiratory distress syndrome (ARDS). The project aims to validate the use of the end tidal alveolar dead space fraction (AVDSF) as a superior marker for mortality risk compared to oxygenation index (OI), as well as determine if AVDSF can identify...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $480,990 to the University of Illinois for a research project focused on accelerating alveolar epithelial regeneration to treat acute respiratory distress syndrome (ARDS). The key objectives are to investigate the role of "aerocytes", a newly identified capillary endothelial cell population, in regulating alveolar...

This Project Grant award of $451,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research conducted by The University of Texas Southwestern Medical Center (UT Southwestern) to develop a human lung alveolus-on-a-chip model for studying non-tuberculous mycobacteria (NTM) infections. The goal is to gain insights into NTM pathogenesis, host-pathogen interactions, and identify potential...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $350,000 to Adiutrix Therapeutics LLC to develop a novel anti-fibrotic compound platform to identify and develop first-in-class therapeutics targeting collagen prolyl-4 hydroxylase (C-P4H) activity. The goal is to treat tissue remodeling and fibrosis in underserved diseases such as idiopathic pulmonary fibrosis (IPF), scleroderma skin fibrosis, kidney fibrosis, and intestinal fibrosis...

This Project Grant award of $402,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to evaluate the use of anti-CD154 monoclonal antibody therapy in a nonhuman primate vascularized composite allograft (VCA) model. The research aims to determine the efficacy of this approach in regulating the host immune response and promoting transplantation tolerance, particularly in sensitized...

This $8.7 million project grant from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), supports the development of patient care technologies for permanent ambulatory artificial lung support from May 2022 to April 2026. Carnegie Mellon University is the primary awardee and will develop technologies to transition a pulmonary assist system to long-term support of chronic lung disease patients. Vanderbilt University Medical...

This $186,408 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to evaluate CD14 as a potential therapeutic target for acute respiratory distress syndrome (ARDS). The project aims to: 1) determine the effects of the CD14-blocking antibody IC14 on cellular targets through blood leukocyte RNA sequencing analysis, 2) examine the relationship between the CD14-pathway biomarker presepsin...